Stopping abruptly reverses these adaptations, sometimes creating a temporary metabolic mismatch where blood sugar regulation is less efficient than before treatment
According to a Boston University study, after one year of GLP-1 use, four in 10 patients will have stopped taking them
PET: positron emission tomography
A mechanistic link reduced active GLP-1 via microbiome/bile-acid changeshas now been demonstrated in humans
Also received honoraria for lectures from Eli Lilly, Boehringer Ingelheim, Novo Nordisk, Sanofi Aventis, AstraZeneca, Gilead, Inova and Merck Sharp & Dohme and has been or is on the advisory boards for Novo Nordisk, Eli Lilly, AstraZeneca, Inova and Pfizer
The digestive tract breaks down amino acid chainsthat's literally one of its primary jobs